Source disclosure: February 12, 2026

ROHTO PHARMACEUTICAL CO.,LTD. [4527.T]

TOKYO, Feb 12 (Pulse News Wire) – ROHTO PHARMACEUTICAL CO.,LTD. (4527) has revised its FY2026/3 Q1 consolidated earnings forecast. FORECAST REVISION SUMMARY: (Unit: ) Revenue Op Profit Ord Profit Net Profit Previous Forecast (A) 338,500 39,500 44,000 32,000 Revised Forecast (B) 340,500 40,500 46,500 33,000 Change (B-A) 2,000 1,000 2,500 1,000 Change (%): Revenue +0.6% | OP +2.5% | OrdP +5.7% | NP +3.1% Prior Year Actual 308,625 38,234 39,725 30,841 KEY CHANGES: - Revenue forecast raised by +0.6% to 340,500 - Net profit forecast raised by +3.1% to 33,000 - Operating profit forecast raised by +2.5% to 40,500 REASON FOR REVISION: 3 November 13, 2025 1¥1501¥20.82 ※202631 DIVIDEND REVISION: The company also revised its dividend forecast.

AI-translated content. 🟢 Confidence: High See terms • Original filing

💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.
🎁 Report 3+ errors with your email and get a free month of premium access